@FierceBiotech: Intercept shares slide as investigators question OCA's safety/efficacy for NASH. Article | Follow @FierceBiotech
@JohnCFierce: That's a big no to $NVS--FDA advisers spurn Novartis' blood cancer drug, putting approval in doubt. Report | Follow @JohnCFierce
@DamianFierce: A biotech developing a concussion treatment has recruited Brett Favre to help it raise money for R&D, because hey. Release | Follow @DamianFierce
@EmilyMFierce: Hey all, today is my last day at Fierce! Please do keep in touch: emily[dot]mullin[at]gmail[dot]com and @emilylmullin. | Follow @EmilyMFierce
> After Salix Pharmaceuticals' ($SLXP) chief financial officer resigned, the company discovered some major accounting inconsistencies, a revelation that sent the drugmaker's shares plummeting. Story
> In two weeks, Sanofi ($SNY) Chairman Serge Weinberg will have to stand before investors and explain how, in the wake of CEO Chris Veihbacher's firing, he plans to return the French company to the marked growth it once knew. More
> The changes to U.S. policy that scared AbbVie ($ABBV) away from buying Shire ($SHPG) will likely prevent Pfizer ($PFE) from making another overture at AstraZeneca ($AZN), the latter company's CEO said. News
Medical Device News
@FierceMedDev: ICYMI: Siemens sells hearing aid biz for $2.7B amid rumors it will exit healthcare entirely. Story | Follow @FierceMedDev
@VarunSaxena2: UPDATE: The new AstraZeneca, University of Manchester center for drug delivery becomes operational in February. FierceDrugDelivery story | Follow @VarunSaxena2
@EmilyWFierce: Google signs onto Foundation Medicine cancer Dx by offering tests to employees. FierceDiagnostics article | Follow @EmilyWFierce
> 'Ambulance drone' for delivering defibrillation could someday save lives. More
> Investigational balloon catheter shows promise in treating peripheral artery disease. Story
> 'Bionic eye' maker Second Sight focused on raising $31.5M in IPO. Article
Pharma News
@FiercePharma: Top-read pharma news Thurs--New numbers back old meme: Pharma does spend more on marketing than R&D. Article | Follow @FiercePharma
@EricPFierce: FDA punishes Ranbaxy for plant problems. Snatches away its approval for generic Nexium. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: ICYMI earlier: This week's full issue of FierceVaccines. Subscribe here. | Follow @CarlyHFierce
> UCB joins pharma's slimdown craze, unloads U.S. generic drug business for $1.53B. More
> Fresenius kills Russian partnership as political tensions escalate. Article